Tomudex
(Raltitrexed)Phase 2Small molecule
Raltitrexed is used to treat certain types of cancer, particularly colorectal cancer. It works by stopping cancer cells from growing and dividing.[1] Tomudex is currently being investigated across 4 indications[3], with its most advanced program in Phase 2.[1]
Tomudex is one of 71 small molecule programs targeting Rectal Adenocarcinoma. It is currently in Phase 2.
4
Indications
32
Total Trials
3
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Tomudex
NNanjing Chia-tai Tianqing Pharmaceutical
Phase 2
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Lamprene
NovartisPreclinical
Emtriva
GileadPreclinical
Foscavir
CClinigen, Inc.
Preclinical
Reminyl
WWim Janssens
Preclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Sirturo
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer11 trials
Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients
Unknown status·—·Phase 2·NCT03053167·100 enrolled
Show 8 more trials
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
Unknown status·—·Phase 1/2·NCT05426811·50 enrolled
Malignant Mesothelioma2 trials
Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004920·256 enrolled
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00004254·25 enrolled
Patients With Advanced Solid Tumors1 trial
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00002902
Pancreatic Cancer1 trial
16 more indications
Metastatic Colorectal Cancer1 trial
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05160896·90 enrolled
Gastric Cancer1 trial
Locally-advanced Rectal Cancer1 trial
Squamous Cell Carcinoma1 trial
Rectal Cancer1 trial
Treatment1 trial
Older Patients1 trial
Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC.
Unknown status·TThe First Affiliated Hospital of Dalian Medical University·Phase 4·NCT03196843·202 enrolled
Hypofractionated Radiotherapy1 trial
Liver Metastases1 trial
Esophageal Cancer1 trial
Head and Neck Squamous Cell Cancer1 trial
First-line Treatment1 trial
Gastroesophageal Junction Adenocarcinoma1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Raltitrexed. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details